SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic and Immunological Vulnerabilities of Colorectal Cancer
Head of the Division of Solid Tumor Oncology
Memorial Sloan Kettering Cancer Center
Director of the Sandra and Edward Meyer Cancer Center
Weill Cornell Medicine and New York-Presbyterian Hospital
Director, Yale Cancer Center
Physician-in-chief, Smilow Cancer Hospital
Professor of Genetics and Genome Science, School of Medicine
Case Western Reserve University
Co-leader, GI Cancer Genetics program (GICG)
Case Comprehensive Cancer Center
The Dream Team focuses on three areas of research that have the potential to impact all stages of colorectal cancer. The emphasis of the first two areas of research is on the potential of immunotherapy and targeted therapy to revolutionize the treatment of colorectal cancer, while the last area of study involves strategies to specifically target different colorectal cancer subtypes.
In addition, the Team seeks to determine the mechanisms of resistance to immunotherapies and targeted therapies, and devise new strategies to overcome the resistance.
The team’s work in correlating genomic features and immune signatures in colorectal cancer has shown that a particular signaling pathway in cancer cells — the Wnt pathway – can be a driver of resistance to immunotherapy. This suggests that the Wnt pathway is a potential target for treatment that would help immunotherapies to work better in defeating the cancer. The Team has shown the potential of aspirin as a treatment for colorectal cancer that is driven by a certain type of genetic mutation. And finally, the Team’s work on cell-free DNA is showing that it can be helpful in detection and treatment of colorectal cancer.
Amount Of Funding
Ryan B. Corcoran, MD, PhD, Massachusetts General Hospital Cancer Center
Nilofer S. Azad, MD, Johns Hopkins University
- Anjee Davis
- Ivelisse M. Page
- Joanna Fuchs, MD
- Martha Raymond
- Thomas Herbert Marsilje
- Vanessa L. Whiting